Comparative effectiveness and safety of direct oral anticoagulants compared to warfarin in morbidly obese patients with acute venous thromboembolism: systematic …
MN Elshafei, MFH Mohamed, A El-Bardissy… - Journal of thrombosis …, 2021 - Springer
Direct oral anticoagulant (DOAC) agents are becoming the anticoagulation strategy of
choice. However, their use in the treatment of acute venous thromboembolism (VTE) in …
choice. However, their use in the treatment of acute venous thromboembolism (VTE) in …
Direct oral anticoagulants in the treatment of acute venous thromboembolism in patients with obesity: a systematic review with meta-analysis
V Mai, E Marceau-Ferron, L Bertoletti, Y Lacasse… - Pharmacological …, 2021 - Elsevier
Background Direct oral anticoagulants'(DOAC) pharmacokinetics are affected by obesity.
Their efficacy and safety in obesity (BMI≥ 30 kg/m 2) and morbid obesity (BMI≥ 40 kg/m 2) …
Their efficacy and safety in obesity (BMI≥ 30 kg/m 2) and morbid obesity (BMI≥ 40 kg/m 2) …
[HTML][HTML] Efficacy and safety of direct oral anticoagulants in venous thromboembolism compared to traditional anticoagulants in morbidly obese patients: a systematic …
Background Randomized clinical trials comparing the efficacy and safety of direct oral
anticoagulants (DOAC) with vitamin K antagonist (VKA) or low molecular weight heparin …
anticoagulants (DOAC) with vitamin K antagonist (VKA) or low molecular weight heparin …
Oral anticoagulant use in morbid obesity and post bariatric surgery: a review
Bariatric surgery has emerged as a therapy for obesity and the associated comorbidities.
Obesity has been shown to be a risk factor for atrial fibrillation as well as venous …
Obesity has been shown to be a risk factor for atrial fibrillation as well as venous …
Direct oral anticoagulants in the treatment of venous thromboembolism: Use in patients with advanced renal impairment, obesity, or other weight-related special …
PP Dobesh, MM Kernan… - Seminars in Respiratory …, 2021 - thieme-connect.com
There are currently more than 7 million patients taking a direct oral anticoagulant (DOAC),
with more new prescriptions per year than warfarin. Despite impressive efficacy and safety …
with more new prescriptions per year than warfarin. Despite impressive efficacy and safety …
Factor Xa inhibitors versus vitamin K antagonist in morbidly obese patients with venous thromboembolism: a systematic review and meta-analysis
Introduction Guidelines have endorsed non-vitamin K antagonist oral anticoagulants
(NOACs), consisting of factor Xa inhibitors (xabans) and direct thrombin inhibitors, as the first …
(NOACs), consisting of factor Xa inhibitors (xabans) and direct thrombin inhibitors, as the first …
Safety and efficacy of direct oral anticoagulants vs warfarin in patients with obesity and venous thromboembolism: a retrospective analysis
ZH Tu, AD Perez, TE Diaz… - Texas Heart Institute …, 2024 - meridian.allenpress.com
Background: Current venous thromboembolism guidelines recommend using direct oral
anticoagulants (DOACs) over warfarin regardless of obesity status; however, evidence …
anticoagulants (DOACs) over warfarin regardless of obesity status; however, evidence …
The “Obesity Paradox” and the use of NOAC
R Bottino, A Carbone, B Liccardo, P Golino… - … : From Pharmacology to …, 2021 - Springer
Obesity is a worldwide health problem at increasing incidence associated with high
morbidity and mortality. Although obesity increases patients' cardiovascular (CV) risk, more …
morbidity and mortality. Although obesity increases patients' cardiovascular (CV) risk, more …
[PDF][PDF] Le traitement de la maladie thromboembolique veineuse: enjeux et nouveautés
V Mai - 2021 - corpus.ulaval.ca
Résumé Introduction: La maladie thromboembolique veineuse (MTEV) est très fréquente.
Les anticoagulants oraux (AOD) ont démontré leur supériorité dans le traitement aigu de …
Les anticoagulants oraux (AOD) ont démontré leur supériorité dans le traitement aigu de …